Cosmos Health Subsidiary Acquires International Nanotechnology Patent, Expands GMP Manufacturing Platform
核心洞察
Cosmos Health's wholly owned subsidiary Cana Laboratories S.A. (搜索) has acquired international patent application WO2025108566A1 from Cloudpharm P.C. (搜索), strengthening its intellectual property portfolio.
The company is pursuing national and regional patent protection across key international markets for the nanotechnology-related technology.
The acquired technology supports next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare product development, leveraging Cana Laboratories' European GMP-certified and EMA-certified manufacturing capabilities.
Cosmos Health Inc. (搜索) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group headquartered in Chicago, announced on June 8, 2026 that its wholly owned subsidiary, Cana Laboratories S.A. (搜索), has acquired ownership of international patent application WO2025108566A1 from Cloudpharm P.C. (搜索) The acquisition marks a significant expansion of the company's intellectual property portfolio and its nanotechnology investment initiatives.
Following the transfer, Cana Laboratories has initiated the process of pursuing patent protection at both national and regional levels across key international markets as part of the company's broader IP strategy. The underlying technology originated from research activities combining early-stage discovery methodologies with advanced pharmaceutical development approaches.
Patent and Intellectual Property Details
The acquired patent application covers technology that supports next-generation product development across multiple healthcare categories, including pharmaceuticals, nutraceuticals, over-the-counter (OTC) products, and specialized healthcare offerings. Cana Laboratories, which holds European Good Manufacturing Practices (GMP) licensing and European Medicines Agency (EMA) certification, will serve as the manufacturing platform for products developed using this technology.
The patent represents an important addition to Cosmos Health's growing innovation portfolio and reflects the company's commitment to transforming advanced scientific discoveries into commercially viable healthcare solutions.
Nanotechnology Investment Initiative
In parallel with the patent acquisition, Cana Laboratories announced plans to expand its investments in nanotechnology-based product development platforms. The company intends to leverage the patented technology, together with additional nanotechnology applications, to support the development of next-generation pharmaceutical, nutraceutical, OTC, and specialized healthcare products.
Integrating proprietary IP with Cana Laboratories' European GMP-certified manufacturing capabilities creates what the company describes as a powerful foundation for the future development of differentiated, high-margin healthcare products. The initiative aligns with Cosmos Health's previously announced strategy of expanding its intellectual property portfolio, strengthening vertical integration, and developing innovative healthcare products supported by advanced technologies and scientific research.
Executive Commentary
Greg Siokas, CEO of Cosmos Health, stated: "This acquisition further strengthens our transition from AI-enabled discovery to proprietary product development and commercialization. By combining intellectual property, advanced formulation technologies, nanotechnology expertise, and our manufacturing infrastructure, we continue to build a scalable innovation platform designed to create long-term shareholder value."
Company Background
Cosmos Health Inc. (搜索), incorporated in 2009 in Nevada, owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub. Through Cana Laboratories S.A. (搜索), the company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. The company has also established R&D partnerships targeting major health disorders such as obesity (搜索), diabetes (搜索), and cancer (搜索), enhanced by artificial intelligence drug repurposing technologies. Cosmos Health operates distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK, with ongoing expansion throughout Europe, Asia, and North America.